Gilead Sciences (GILD) stock in focus as the company joins The Global Fund to expand access to lenacapavir, an HIV PrEP ...

The drugmaker will provide, at no profit, doses to treat up to 2 million people in resource-limited countries. Meanwhile, Arvinas' John Houston is retiring from his role leading the biotech.

Gilead Sciences and the Global Fund to Fight AIDS, Tuberculosis and Malaria said on Wednesday they had finalised plans to ...

Lower-income countries will gain access to a "game-changing" HIV prevention drug with a new deal signed between US ...

Gilead announced a deal to get its groundbreaking HIV prevention drug to lower income countries. Notably, the deal does not ...

Lenacapavir offers twice-yearly HIV prevention with near-complete protection in clinical trials. Clinical trials show ...

Lenacapavir, the first FDA-approved, twice-yearly injectable PrEP for HIV prevention, shows 96% efficacy and offers ...

GILD jumps 27.2% in six months as FDA nod for twice-yearly HIV drug Yeztugo boosts its HIV franchise and growth outlook.

The fact that lenacapavir will soon be available to patients is a testament to the strength of America's biopharmaceutical ...

GSK specialty medicines grew YoY in Q1 2025, and it is now the main profit engine, offsetting the weakness in their vaccine ...

Trump administration funding cuts and dismantling of USAID force the focus to shift from elimination back to treatment.